CytomX Therapeutics, Inc.
CTMX
$0.9605
-$0.0059-0.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 138.10M | 126.62M | 119.57M | 119.18M | 101.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 138.10M | 126.62M | 119.57M | 119.18M | 101.21M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 138.10M | 126.62M | 119.57M | 119.18M | 101.21M |
| SG&A Expenses | 29.73M | 31.93M | 30.79M | 29.80M | 30.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.11M | 119.91M | 113.85M | 108.35M | 107.70M |
| Operating Income | 25.00M | 6.71M | 5.72M | 10.83M | -6.48M |
| Income Before Tax | 32.09M | 15.06M | 15.08M | 20.47M | 3.32M |
| Income Tax Expenses | 223.00K | 1.23M | 3.99M | 3.94M | 3.89M |
| Earnings from Continuing Operations | 31.87 | 13.83 | 11.09 | 16.53 | -0.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.87M | 13.83M | 11.09M | 16.53M | -569.00K |
| EBIT | 25.00M | 6.71M | 5.72M | 10.83M | -6.48M |
| EBITDA | 26.76M | 8.55M | 7.62M | 12.87M | -4.31M |
| EPS Basic | 0.38 | 0.17 | 0.14 | 0.20 | -0.02 |
| Normalized Basic EPS | 0.24 | 0.11 | 0.12 | 0.15 | 0.02 |
| EPS Diluted | 0.38 | 0.16 | 0.13 | 0.19 | -0.02 |
| Normalized Diluted EPS | 0.24 | 0.11 | 0.12 | 0.15 | 0.02 |
| Average Basic Shares Outstanding | 337.75M | 333.56M | 329.20M | 310.85M | 295.07M |
| Average Diluted Shares Outstanding | 338.46M | 334.27M | 330.06M | 311.71M | 295.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |